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antitrust and trade regulation bulletin FTC
Releases Report on Intellectual Property and
Antitrust
James Burling, John C. Christie Jr., and Michelle Miller

Abstract

Last year the FTC and the Department of Justice jointly held hearings focused
on the current balance of competition and patent law and policy. (See our December, 2001 Antitrust and Trade Regulation Bulletin at www.haledorr.com/antitrust.)
The hearings spanned more than 24 days, involving more than 300 panelists and
100 separate written submissions. The first tangible by-product of those sessions
came on October 28, 2003, with the release of a 266-page FTC report containing
specific recommendations for changes in the existing patent system (the Patent Report)(http://www.ftc.gov/opa/2003/10/creport .htm). A second, joint report with
DOJ, containing specific recommendations for antitrust, is promised for the future.

on the preparation of a discussion of other issues

accomplish the purposes of the antitrust laws.

that have not been the subject of written

For parties to consummated mergers challenged

confirmation.
Although the manual brings the materials

agency may seek not only to dissolve the

completely up-to-date, incorporating the PNO’s

transaction but also, in “exceptional”

latest positions on various issues and adding

circumstances, to have the parties repay profits

summaries of interpretations relating to changes

earned while operating as a merged company.

that have occurred in the HSR laws since 1991,

However, as with all such statements of policy,

new rules and interpretations of the Act are

the true import of this pronouncement will not be

constantly occurring. As a result, parties requiring

known until the FTC puts it into practice.

advice on HSR issues should continue to consult

The Section of Antitrust Law of the American Bar
Association has published the third edition of the
Premerger Notification Practice Manual. The
manual provides summaries and discussions of
both the informal interpretations of the Hart-ScottRodino Antitrust Improvements Act of 1976 (HSR
or the Act) given by the Premerger Notification
Office of the Federal Trade Commission (PNO)
and enforcement actions brought by the antitrust
agencies related to the Act. Hy David Rubenstein
of Hale and Dorr LLP’s Antitrust and Trade
Regulation Group, formerly an attorney with the
PNO, was a member of the working group that
developed and edited the third edition.
The Act authorizes the PNO to provide informal,
typically oral, interpretations as well as formal
written interpretations of HSR issues. Although
the PNO has issued only 17 formal written
interpretations in the 27 years since the Act was
passed, the office has issued thousands of informal
oral interpretations. Many of these oral
interpretations have been confirmed in written
correspondence to the PNO. These written
confirmations formed the basis of the first two
editions of the manual, published in 1985 and
1991. This third edition of the manual continues
to be the most comprehensive published source
for such information to date. In addition, the
editors of this edition collaborated with the PNO
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a former New York assistant first deputy attorney

Patent & Trademark Office.

general. Her term extends until September 2009.
Joseph J. Simmons recently resigned his position
as the director of the Bureau of Competition.
Simmons presided over 60 enforcement actions
during his two years at the Commission, including
25 non-merger cases and two challenges to
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serve as the deputy assistant attorney general for
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Department of
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Trade Commission
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changes in recent
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in the General Electric–Honeywell International
and Microsoft cases.
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Oxford
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Commissioner Sheila Foster Anthony served on

Princeton
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the Commission for nearly six years until her term
expired recently. Often a dissenting voice,

Reston
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Commissioner Anthony disagreed with other
commissioners in the cruise industry consolidation,

private sector as an economic consultant and
adjunct professor at Vanderbilt University. Luke
Froeb will replace Scheffman. Froeb joins the
FTC from the Owen Graduate School of
Management at Vanderbilt University. Froeb was
previously an economist with the Antitrust Division.
The FTC recently enhanced its intellectual property
expertise, evidencing yet more institutional interest

General Mills–Pillsbury merger decisions. Pamela

Irizarry comes from Michigan State University,
where he was teaching law.
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the patent. As the FTC sees it, the two systems

(See our December, 2001 Antitrust and Trade

Regulation Bulletin at www.haledorr.com/antitrust.)
The hearings spanned more than 24 days,
involving more than 300 panelists and 100
separate written submissions. The first tangible
by-product of those sessions came on October
28, 2003, with the release of a 266-page FTC
report containing specific recommendations for
changes in the existing patent system (the Patent
Report)(http://www.ftc.gov/opa/2003/10/creport
.htm). A second, joint report with DOJ, containing
specific recommendations for antitrust, is promised
for the future.

Although the Patent Report states that “for the
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The Patent Report begins with a general discussion

contain claims that are overly broad. These poor

of the common aims of both competition and

quality or questionable patents can cause

patent law and policy. Competition stimulates

competitors to forgo R&D in the areas the patent

innovation by spurring the innovation of new or

improperly covers, and can increase the practice

This publication is not intended as legal advice. Readers should not act upon
information contained in this publication without professional legal counseling.

better products or more efficient processes. Patent

of “defensive patenting,” contribute to the “patent
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most part” the patent system achieves a proper
balance with competition policy, it concludes that
in some ways the system is “out of balance.” As
a result, the report makes a number of specific

FTC recommends
sweeping changes
in the balance
between competition
and patent law.

recommendations for reforming the legal systems,
procedures and institutions of the patent system.
Most, but not all, of the proposals would require
enabling legislation. The FTC’s recommendations
include the following:
1. Measures should be implemented to reduce
the number of invalid patents issued or those that

Mays joined as counsels for intellectual property.

Washington
202 942 8400
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making, using or selling the invention claimed by

in this subject. Armando Irizarry and Thomas
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781 966 2000

and in the PepsiCo–Quaker Oats (Gatorade) and

the innovator with a right to exclude others from
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thicket” and create licensing complexities and

the patent had finally issued, that it was infringing.

Obviously many of these recommendations would

manufacturer $40 million per year, payable

inhibiting competition by paying the only potential

the Eleventh Circuit’s analysis because the

costs. In order to address this issue, the Patent

Relatively recently, the law was changed to require

result in significant changes to both patent law

quarterly, from July 1998 until the termination of

competitor $40 million per year to stay out of the

reasonableness of such agreements is to be

Report recommends a variety of changes in the

the publishing of all patent applications except

and practice, affecting a wide variety of industries.

the litigation. In return, the generic manufacturer

market.” Id.

judged at the time the agreements were entered

existing patent system:

those filed only within the United States. The

Whether Congress shares the FTC’s concerns,

agreed not to bring its generic product to market

Patent Report recommends the elimination of this

and is ready to enact major legislation to address

even though, under the law, the generic product

exception to publication, in the interests of

those concerns, remains to be seen.

could have been marketed from that date forward

a) The first change would be the introduction of
legislation to create a new administrative
procedure to allow post-grant review of, and
opposition to, patents. This procedure would

evidence” to a “preponderance of the
evidence.” According to the Patent Report,
the existing circumstances surrounding the
issuance of a patent by the U.S. Patent and

would result

Trademark Office (PTO) suggest that an
overly strong presumption of a patent’s validity

in significant

is inappropriate.

changes to both

c) The third recommended change is a general
tightening in the legal standards used to

patent law

evaluate whether an invention is “obvious”

and practice.

from infringement allegations that rely on patent
claims first introduced in a continuing or other

or not, in order to better assure that a
development is significant enough to merit
a patent.
d) Lastly, the Patent Report proposes that the

infringement).

because the patent is subsequently declared invalid
would undermine the patent incentives.” Id.

for patent infringement as they were pursuing

court to determine the actual competitive effects

Two United States circuit courts of appeals have

the FDA approved a reformulated version of the

FDA approval for their generic versions of Abbott’s

of the agreements in light of all the circumstances.

reached opposite conclusions regarding the

generic drug that the generic manufacturer

pioneer drug, Hytrin. Before the termination of

“To hold that an ostensibly reasonable settlement

similar patent application. The Patent Report

appropriate antitrust analysis to apply to a payment

certified did not infringe the patent at issue. With

the infringement litigation, Abbott, Zenith and

of patent litigation gives rise to per se antitrust

concludes that, if the patent applicant uses

by a patent holder to an alleged infringer in settling

that approval, the two companies settled the

Geneva entered into interim agreements by which

liability if it involves any payment by the patentee

procedures such as continuing applications to

patent infringement litigation. First, in June, the

litigation, with the branded manufacturer paying

the generics agreed not to enter the market and

would obviously chill such settlements, thereby

extend the period of patent prosecution, the

Conflicting court

Abbott agreed to make substantial periodic

increasing the cost of patent enforcement and

payments. The payments were to be reduced in

decreasing the value of patent protection

rulings leave

the event another generic entered the market and

generally.” Id.

says challenged

These two conflicting opinions create considerable

consummated

Sixth Circuit found such payments (and the

nearly $51 million in additional funds to the generic

potential for anticompetitive hold-up increases.

settlement agreements incorporating them) to be

manufacturer.

Intervening or prior-user rights should shelter

per se illegal under the antitrust laws. In re
Cardizem CD Antitrust Litigation, No. 00-24836
(6th Cir. June 13, 2003). More recently, the
Eleventh Circuit declined to find similar a patent
infringement settlement per se illegal even though
the patent holder paid the alleged infringers and
the patent was later held invalid. Valley Drug Co.
v. Geneva Pharma., No. 02-12091 (11th Cir. Sept
15, 2003). The Eleventh Circuit acknowledged
that its analysis ran contrary to the Sixth Circuit.
The split in the circuits on this issue may ultimately
invite Supreme Court review.

inventors and users that infringe a patent only as
a result of claim amendments following a
continuation, provided that the sheltered invention
was developed and used before the amended
claims were published.
4. Legislation should be enacted to require—as
a predicate for liability for willful infringement—
a patentee to either show actual, written notice
of infringement, or to demonstrate that the infringer
deliberately copied the patentee’s invention,
knowing it to be patented. According to the Patent
Report, this requirement would allow firms to read

In the case before the Sixth Circuit, Hoescht

to address issues of patent quality, and that

patents for their disclosure value and to survey

Marion Roussel, the manufacturer of the

various PTO procedural rules and regulations

the patent landscape without risking liability for

prescription drug Cardizem CD, sued Andrx

be modified to enable it to improve the process

willful infringement.

Pharmaceuticals—then a potential manufacturer

5. Finally, the FTC promises to take steps to

2. Legislation should be enacted to require the

increase communication between the antitrust

publication of all patent applications 18 months

agencies and the patent institutions. These steps

after the filing of the application. During the time

will include filing amicus briefs in important patent

that otherwise passes between the filing of a

cases, asking the PTO Director to reexamine

patent application and the issuance of a patent,

questionable patents that raise competitive

an applicant’s competitor could have invested

concerns and establishing a Liaison Panel between

substantially in designing and developing a product

the FTC, the DOJ and the PTO.

and bringing it to market, only to discover, once
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two generic manufacturers—Zenith Goldline

reasonably within the scope of the patent merely

The litigation finally ended in June 1999 when

PTO be provided with the funding necessary

of patent issuance.

Laboratories, the branded manufacturer, sued

for the exclusionary effects of a settlement

As a result, the case was remanded to the district

intervening or prior user rights to protect parties

from the present “clear and convincing

in essential respects. In Valley Drug, Abbott

into. “Exposing settling parties to antitrust liability

Pharmaceuticals and Geneva Pharmaceuticals—

to patent validity short of federal court litigation.

governing challenges to the validity of a patent

recommendations

if the litigation resulted in a finding of patent

3. Legislation should be enacted to create

of legislation to modify the legal standard

Many of the FTC’s

Circuits Disagree over Per
Se Treatment of Agreements to
Settle Patent Infringement Suits

be designed to allow for meaningful challenges

b) The second change would be the enactment

significantly different from the one in Cardizem

(subject, of course, to damages for infringement

increasing business certainty and promoting
rational planning.

The challenged agreement in Valley Drug was not
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of a generic version of that drug—in January
1996, alleging patent infringement. While the
litigation was pending, the FDA approved the
generic version, allowing it to go to market at the
latest in July 1998 and perhaps sooner if the
litigation resulted in a finding of non-infringement.
Shortly after the FDA decision, the two companies
entered an interim agreement by which the
branded manufacturer agreed to pay the generic

On a motion for partial summary judgment, the

significant

district court determined that the interim
agreement was an illegal restraint of trade and
certified the issue for interlocutory appeal. The
Sixth Circuit held that the interim agreement was
“a naked horizontal restraint of trade that is per

suit. Abbott, however, lost the patent litigation at

unresolved

the district court level in 1998 and after appeal

questions

investigation, the agreements were terminated in

surrounding

se illegal because it is presumed to have the effect
of reducing competition in the market for [the
branded drug] and its generic equivalents to the
detriment of consumers.” In re Cardizem, No.
00-24836 (6th Cir. June 12, 2003). The court
concluded that the agreement was of the type
that predictably resulted in antitrust injury because
at its core it eliminated competition in the market
for the drug.

were to cease if Abbott ultimately won its patent

the status of
patent settlements.

in 1999. In apparent response to an FTC
August 1999.
Unlike the Cardizem court, the Valley Drug court
of the agreements “are at the heart of the patent
right and cannot trigger the per se label.” Id. In
by the district court, the Eleventh Circuit found
that, because the patent gave Abbott the right to
exclusively market its drug until 2014, any
agreement merely continuing its right to exclusivity
did not necessarily impair competition. “If Abbott

characterization of the agreement as an attempt

had a lawful right to exclude competitors, it is not

to enforce a patent or to settle litigation. Instead,

obvious that competition was limited more than

it saw the agreement as a way for the branded

that lawful degree by paying potential competitors

manufacturer to share its monopoly profits with

for their exit.” Valley Drug Co. v. Geneva Pharma.,

its only potential competitor in an effort to prolong

No. 02-12091 (11th Cir. Sept 15, 2003).

the patent monopoly as long as possible. “[I]t is

suits (or entering into agreements pending the
outcome of the litigation) in similar circumstances.
They suggest the need for great care in crafting
such settlements because both private litigation
and government investigations may result.

determined that the alleged exclusionary aspects

reversing a grant of partial summary judgment

In so finding, the court refused to accept a

uncertainty for parties settling patent infringement

FTC Clarifies Use of Monetary
Remedies in Competition
Cases
The FTC recently issued a policy statement on
the use of monetary equitable remedies such as
disgorgement and restitution in competition cases.
While the Commission will continue to rely primarily
on traditional, prospective remedies, the statement
suggests that disgorgement and restitution will
be sought in “exceptional” circumstances. Three
factors are identified that will be considered in
this determination. First, whether the underlying
violation is clear. Second, whether there is a

one thing to take advantage of a monopoly that

The fact that Abbott’s patent had later been

reasonable basis for calculating the amount of

naturally arises from a patent, but another thing

determined to be invalid was of no relevance to

the remedial payment. Third, whether other

altogether to bolster the patent’s effectiveness in
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FTC policy statement

mergers may be
subject to
disgorgement
in “exceptional”
circumstances.

thicket” and create licensing complexities and

the patent had finally issued, that it was infringing.

Obviously many of these recommendations would

manufacturer $40 million per year, payable

inhibiting competition by paying the only potential

the Eleventh Circuit’s analysis because the

costs. In order to address this issue, the Patent

Relatively recently, the law was changed to require

result in significant changes to both patent law

quarterly, from July 1998 until the termination of

competitor $40 million per year to stay out of the

reasonableness of such agreements is to be

Report recommends a variety of changes in the

the publishing of all patent applications except

and practice, affecting a wide variety of industries.
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judged at the time the agreements were entered
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Whether Congress shares the FTC’s concerns,

agreed not to bring its generic product to market

Patent Report recommends the elimination of this

and is ready to enact major legislation to address

even though, under the law, the generic product

exception to publication, in the interests of

those concerns, remains to be seen.

could have been marketed from that date forward

a) The first change would be the introduction of
legislation to create a new administrative
procedure to allow post-grant review of, and
opposition to, patents. This procedure would

evidence” to a “preponderance of the
evidence.” According to the Patent Report,
the existing circumstances surrounding the
issuance of a patent by the U.S. Patent and

would result

Trademark Office (PTO) suggest that an
overly strong presumption of a patent’s validity

in significant

is inappropriate.

changes to both

c) The third recommended change is a general
tightening in the legal standards used to

patent law

evaluate whether an invention is “obvious”

and practice.

from infringement allegations that rely on patent
claims first introduced in a continuing or other

or not, in order to better assure that a
development is significant enough to merit
a patent.
d) Lastly, the Patent Report proposes that the

infringement).

because the patent is subsequently declared invalid
would undermine the patent incentives.” Id.

for patent infringement as they were pursuing

court to determine the actual competitive effects

Two United States circuit courts of appeals have

the FDA approved a reformulated version of the

FDA approval for their generic versions of Abbott’s

of the agreements in light of all the circumstances.

reached opposite conclusions regarding the
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“To hold that an ostensibly reasonable settlement

similar patent application. The Patent Report

appropriate antitrust analysis to apply to a payment
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concludes that, if the patent applicant uses
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that approval, the two companies settled the
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would obviously chill such settlements, thereby

extend the period of patent prosecution, the

Conflicting court

Abbott agreed to make substantial periodic

increasing the cost of patent enforcement and

payments. The payments were to be reduced in

decreasing the value of patent protection

rulings leave

the event another generic entered the market and

generally.” Id.

says challenged

These two conflicting opinions create considerable

consummated

Sixth Circuit found such payments (and the

nearly $51 million in additional funds to the generic

potential for anticompetitive hold-up increases.

settlement agreements incorporating them) to be

manufacturer.

Intervening or prior-user rights should shelter

per se illegal under the antitrust laws. In re
Cardizem CD Antitrust Litigation, No. 00-24836
(6th Cir. June 13, 2003). More recently, the
Eleventh Circuit declined to find similar a patent
infringement settlement per se illegal even though
the patent holder paid the alleged infringers and
the patent was later held invalid. Valley Drug Co.
v. Geneva Pharma., No. 02-12091 (11th Cir. Sept
15, 2003). The Eleventh Circuit acknowledged
that its analysis ran contrary to the Sixth Circuit.
The split in the circuits on this issue may ultimately
invite Supreme Court review.
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a result of claim amendments following a
continuation, provided that the sheltered invention
was developed and used before the amended
claims were published.
4. Legislation should be enacted to require—as
a predicate for liability for willful infringement—
a patentee to either show actual, written notice
of infringement, or to demonstrate that the infringer
deliberately copied the patentee’s invention,
knowing it to be patented. According to the Patent
Report, this requirement would allow firms to read

In the case before the Sixth Circuit, Hoescht

to address issues of patent quality, and that

patents for their disclosure value and to survey
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various PTO procedural rules and regulations
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be modified to enable it to improve the process
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5. Finally, the FTC promises to take steps to

2. Legislation should be enacted to require the

increase communication between the antitrust

publication of all patent applications 18 months

agencies and the patent institutions. These steps

after the filing of the application. During the time

will include filing amicus briefs in important patent

that otherwise passes between the filing of a

cases, asking the PTO Director to reexamine

patent application and the issuance of a patent,

questionable patents that raise competitive

an applicant’s competitor could have invested

concerns and establishing a Liaison Panel between

substantially in designing and developing a product

the FTC, the DOJ and the PTO.

and bringing it to market, only to discover, once
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two generic manufacturers—Zenith Goldline

reasonably within the scope of the patent merely

The litigation finally ended in June 1999 when

PTO be provided with the funding necessary

of patent issuance.

Laboratories, the branded manufacturer, sued

for the exclusionary effects of a settlement

As a result, the case was remanded to the district

intervening or prior user rights to protect parties

from the present “clear and convincing

in essential respects. In Valley Drug, Abbott

into. “Exposing settling parties to antitrust liability

Pharmaceuticals and Geneva Pharmaceuticals—

to patent validity short of federal court litigation.

governing challenges to the validity of a patent

recommendations

if the litigation resulted in a finding of patent

3. Legislation should be enacted to create

of legislation to modify the legal standard

Many of the FTC’s

Circuits Disagree over Per
Se Treatment of Agreements to
Settle Patent Infringement Suits

be designed to allow for meaningful challenges

b) The second change would be the enactment

significantly different from the one in Cardizem

(subject, of course, to damages for infringement

increasing business certainty and promoting
rational planning.

The challenged agreement in Valley Drug was not

of a generic version of that drug—in January
1996, alleging patent infringement. While the
litigation was pending, the FDA approved the
generic version, allowing it to go to market at the
latest in July 1998 and perhaps sooner if the
litigation resulted in a finding of non-infringement.
Shortly after the FDA decision, the two companies
entered an interim agreement by which the
branded manufacturer agreed to pay the generic
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On a motion for partial summary judgment, the

significant

district court determined that the interim
agreement was an illegal restraint of trade and
certified the issue for interlocutory appeal. The
Sixth Circuit held that the interim agreement was
“a naked horizontal restraint of trade that is per

suit. Abbott, however, lost the patent litigation at

unresolved

the district court level in 1998 and after appeal

questions

investigation, the agreements were terminated in

surrounding

se illegal because it is presumed to have the effect
of reducing competition in the market for [the
branded drug] and its generic equivalents to the
detriment of consumers.” In re Cardizem, No.
00-24836 (6th Cir. June 12, 2003). The court
concluded that the agreement was of the type
that predictably resulted in antitrust injury because
at its core it eliminated competition in the market
for the drug.

were to cease if Abbott ultimately won its patent

the status of
patent settlements.

in 1999. In apparent response to an FTC
August 1999.
Unlike the Cardizem court, the Valley Drug court
of the agreements “are at the heart of the patent
right and cannot trigger the per se label.” Id. In
by the district court, the Eleventh Circuit found
that, because the patent gave Abbott the right to
exclusively market its drug until 2014, any
agreement merely continuing its right to exclusivity
did not necessarily impair competition. “If Abbott

characterization of the agreement as an attempt

had a lawful right to exclude competitors, it is not

to enforce a patent or to settle litigation. Instead,

obvious that competition was limited more than

it saw the agreement as a way for the branded

that lawful degree by paying potential competitors

manufacturer to share its monopoly profits with

for their exit.” Valley Drug Co. v. Geneva Pharma.,

its only potential competitor in an effort to prolong

No. 02-12091 (11th Cir. Sept 15, 2003).

the patent monopoly as long as possible. “[I]t is

suits (or entering into agreements pending the
outcome of the litigation) in similar circumstances.
They suggest the need for great care in crafting
such settlements because both private litigation
and government investigations may result.

determined that the alleged exclusionary aspects

reversing a grant of partial summary judgment

In so finding, the court refused to accept a

uncertainty for parties settling patent infringement

FTC Clarifies Use of Monetary
Remedies in Competition
Cases
The FTC recently issued a policy statement on
the use of monetary equitable remedies such as
disgorgement and restitution in competition cases.
While the Commission will continue to rely primarily
on traditional, prospective remedies, the statement
suggests that disgorgement and restitution will
be sought in “exceptional” circumstances. Three
factors are identified that will be considered in
this determination. First, whether the underlying
violation is clear. Second, whether there is a

one thing to take advantage of a monopoly that

The fact that Abbott’s patent had later been

reasonable basis for calculating the amount of

naturally arises from a patent, but another thing

determined to be invalid was of no relevance to

the remedial payment. Third, whether other

altogether to bolster the patent’s effectiveness in
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thicket” and create licensing complexities and

the patent had finally issued, that it was infringing.

Obviously many of these recommendations would

manufacturer $40 million per year, payable

inhibiting competition by paying the only potential

the Eleventh Circuit’s analysis because the

costs. In order to address this issue, the Patent

Relatively recently, the law was changed to require

result in significant changes to both patent law

quarterly, from July 1998 until the termination of

competitor $40 million per year to stay out of the

reasonableness of such agreements is to be

Report recommends a variety of changes in the

the publishing of all patent applications except

and practice, affecting a wide variety of industries.

the litigation. In return, the generic manufacturer

market.” Id.

judged at the time the agreements were entered

existing patent system:

those filed only within the United States. The

Whether Congress shares the FTC’s concerns,

agreed not to bring its generic product to market

Patent Report recommends the elimination of this

and is ready to enact major legislation to address

even though, under the law, the generic product

exception to publication, in the interests of

those concerns, remains to be seen.

could have been marketed from that date forward

a) The first change would be the introduction of
legislation to create a new administrative
procedure to allow post-grant review of, and
opposition to, patents. This procedure would

evidence” to a “preponderance of the
evidence.” According to the Patent Report,
the existing circumstances surrounding the
issuance of a patent by the U.S. Patent and

would result

Trademark Office (PTO) suggest that an
overly strong presumption of a patent’s validity

in significant

is inappropriate.

changes to both

c) The third recommended change is a general
tightening in the legal standards used to

patent law

evaluate whether an invention is “obvious”

and practice.

from infringement allegations that rely on patent
claims first introduced in a continuing or other

or not, in order to better assure that a
development is significant enough to merit
a patent.
d) Lastly, the Patent Report proposes that the

infringement).

because the patent is subsequently declared invalid
would undermine the patent incentives.” Id.

for patent infringement as they were pursuing

court to determine the actual competitive effects

Two United States circuit courts of appeals have

the FDA approved a reformulated version of the

FDA approval for their generic versions of Abbott’s

of the agreements in light of all the circumstances.

reached opposite conclusions regarding the

generic drug that the generic manufacturer

pioneer drug, Hytrin. Before the termination of

“To hold that an ostensibly reasonable settlement

similar patent application. The Patent Report

appropriate antitrust analysis to apply to a payment

certified did not infringe the patent at issue. With

the infringement litigation, Abbott, Zenith and

of patent litigation gives rise to per se antitrust

concludes that, if the patent applicant uses

by a patent holder to an alleged infringer in settling

that approval, the two companies settled the

Geneva entered into interim agreements by which

liability if it involves any payment by the patentee

procedures such as continuing applications to

patent infringement litigation. First, in June, the

litigation, with the branded manufacturer paying

the generics agreed not to enter the market and

would obviously chill such settlements, thereby

extend the period of patent prosecution, the

Conflicting court

Abbott agreed to make substantial periodic

increasing the cost of patent enforcement and

payments. The payments were to be reduced in

decreasing the value of patent protection

rulings leave

the event another generic entered the market and

generally.” Id.

says challenged

These two conflicting opinions create considerable

consummated

Sixth Circuit found such payments (and the

nearly $51 million in additional funds to the generic

potential for anticompetitive hold-up increases.

settlement agreements incorporating them) to be

manufacturer.

Intervening or prior-user rights should shelter

per se illegal under the antitrust laws. In re
Cardizem CD Antitrust Litigation, No. 00-24836
(6th Cir. June 13, 2003). More recently, the
Eleventh Circuit declined to find similar a patent
infringement settlement per se illegal even though
the patent holder paid the alleged infringers and
the patent was later held invalid. Valley Drug Co.
v. Geneva Pharma., No. 02-12091 (11th Cir. Sept
15, 2003). The Eleventh Circuit acknowledged
that its analysis ran contrary to the Sixth Circuit.
The split in the circuits on this issue may ultimately
invite Supreme Court review.

inventors and users that infringe a patent only as
a result of claim amendments following a
continuation, provided that the sheltered invention
was developed and used before the amended
claims were published.
4. Legislation should be enacted to require—as
a predicate for liability for willful infringement—
a patentee to either show actual, written notice
of infringement, or to demonstrate that the infringer
deliberately copied the patentee’s invention,
knowing it to be patented. According to the Patent
Report, this requirement would allow firms to read

In the case before the Sixth Circuit, Hoescht

to address issues of patent quality, and that

patents for their disclosure value and to survey

Marion Roussel, the manufacturer of the

various PTO procedural rules and regulations

the patent landscape without risking liability for

prescription drug Cardizem CD, sued Andrx

be modified to enable it to improve the process

willful infringement.

Pharmaceuticals—then a potential manufacturer

5. Finally, the FTC promises to take steps to

2. Legislation should be enacted to require the

increase communication between the antitrust

publication of all patent applications 18 months

agencies and the patent institutions. These steps

after the filing of the application. During the time

will include filing amicus briefs in important patent

that otherwise passes between the filing of a

cases, asking the PTO Director to reexamine

patent application and the issuance of a patent,

questionable patents that raise competitive

an applicant’s competitor could have invested

concerns and establishing a Liaison Panel between

substantially in designing and developing a product

the FTC, the DOJ and the PTO.

and bringing it to market, only to discover, once
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two generic manufacturers—Zenith Goldline

reasonably within the scope of the patent merely

The litigation finally ended in June 1999 when

PTO be provided with the funding necessary

of patent issuance.

Laboratories, the branded manufacturer, sued

for the exclusionary effects of a settlement

As a result, the case was remanded to the district

intervening or prior user rights to protect parties

from the present “clear and convincing

in essential respects. In Valley Drug, Abbott

into. “Exposing settling parties to antitrust liability

Pharmaceuticals and Geneva Pharmaceuticals—

to patent validity short of federal court litigation.

governing challenges to the validity of a patent

recommendations

if the litigation resulted in a finding of patent

3. Legislation should be enacted to create

of legislation to modify the legal standard

Many of the FTC’s

Circuits Disagree over Per
Se Treatment of Agreements to
Settle Patent Infringement Suits

be designed to allow for meaningful challenges

b) The second change would be the enactment

significantly different from the one in Cardizem

(subject, of course, to damages for infringement

increasing business certainty and promoting
rational planning.

The challenged agreement in Valley Drug was not

of a generic version of that drug—in January
1996, alleging patent infringement. While the
litigation was pending, the FDA approved the
generic version, allowing it to go to market at the
latest in July 1998 and perhaps sooner if the
litigation resulted in a finding of non-infringement.
Shortly after the FDA decision, the two companies
entered an interim agreement by which the
branded manufacturer agreed to pay the generic

On a motion for partial summary judgment, the

significant

district court determined that the interim
agreement was an illegal restraint of trade and
certified the issue for interlocutory appeal. The
Sixth Circuit held that the interim agreement was
“a naked horizontal restraint of trade that is per

suit. Abbott, however, lost the patent litigation at

unresolved

the district court level in 1998 and after appeal

questions

investigation, the agreements were terminated in

surrounding

se illegal because it is presumed to have the effect
of reducing competition in the market for [the
branded drug] and its generic equivalents to the
detriment of consumers.” In re Cardizem, No.
00-24836 (6th Cir. June 12, 2003). The court
concluded that the agreement was of the type
that predictably resulted in antitrust injury because
at its core it eliminated competition in the market
for the drug.

were to cease if Abbott ultimately won its patent

the status of
patent settlements.

in 1999. In apparent response to an FTC
August 1999.
Unlike the Cardizem court, the Valley Drug court
of the agreements “are at the heart of the patent
right and cannot trigger the per se label.” Id. In
by the district court, the Eleventh Circuit found
that, because the patent gave Abbott the right to
exclusively market its drug until 2014, any
agreement merely continuing its right to exclusivity
did not necessarily impair competition. “If Abbott

characterization of the agreement as an attempt

had a lawful right to exclude competitors, it is not

to enforce a patent or to settle litigation. Instead,

obvious that competition was limited more than

it saw the agreement as a way for the branded

that lawful degree by paying potential competitors

manufacturer to share its monopoly profits with

for their exit.” Valley Drug Co. v. Geneva Pharma.,

its only potential competitor in an effort to prolong

No. 02-12091 (11th Cir. Sept 15, 2003).

the patent monopoly as long as possible. “[I]t is

suits (or entering into agreements pending the
outcome of the litigation) in similar circumstances.
They suggest the need for great care in crafting
such settlements because both private litigation
and government investigations may result.

determined that the alleged exclusionary aspects

reversing a grant of partial summary judgment

In so finding, the court refused to accept a

uncertainty for parties settling patent infringement
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The FTC recently issued a policy statement on
the use of monetary equitable remedies such as
disgorgement and restitution in competition cases.
While the Commission will continue to rely primarily
on traditional, prospective remedies, the statement
suggests that disgorgement and restitution will
be sought in “exceptional” circumstances. Three
factors are identified that will be considered in
this determination. First, whether the underlying
violation is clear. Second, whether there is a

one thing to take advantage of a monopoly that

The fact that Abbott’s patent had later been

reasonable basis for calculating the amount of

naturally arises from a patent, but another thing

determined to be invalid was of no relevance to

the remedial payment. Third, whether other

altogether to bolster the patent’s effectiveness in
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on the preparation of a discussion of other issues

accomplish the purposes of the antitrust laws.

that have not been the subject of written

For parties to consummated mergers challenged

confirmation.
Although the manual brings the materials

agency may seek not only to dissolve the

completely up-to-date, incorporating the PNO’s

transaction but also, in “exceptional”

latest positions on various issues and adding

circumstances, to have the parties repay profits

summaries of interpretations relating to changes

earned while operating as a merged company.

that have occurred in the HSR laws since 1991,

However, as with all such statements of policy,

new rules and interpretations of the Act are

the true import of this pronouncement will not be

constantly occurring. As a result, parties requiring

known until the FTC puts it into practice.

advice on HSR issues should continue to consult

The Section of Antitrust Law of the American Bar
Association has published the third edition of the
Premerger Notification Practice Manual. The
manual provides summaries and discussions of
both the informal interpretations of the Hart-ScottRodino Antitrust Improvements Act of 1976 (HSR
or the Act) given by the Premerger Notification
Office of the Federal Trade Commission (PNO)
and enforcement actions brought by the antitrust
agencies related to the Act. Hy David Rubenstein
of Hale and Dorr LLP’s Antitrust and Trade
Regulation Group, formerly an attorney with the
PNO, was a member of the working group that
developed and edited the third edition.
The Act authorizes the PNO to provide informal,
typically oral, interpretations as well as formal
written interpretations of HSR issues. Although
the PNO has issued only 17 formal written
interpretations in the 27 years since the Act was
passed, the office has issued thousands of informal
oral interpretations. Many of these oral
interpretations have been confirmed in written
correspondence to the PNO. These written
confirmations formed the basis of the first two
editions of the manual, published in 1985 and
1991. This third edition of the manual continues
to be the most comprehensive published source
for such information to date. In addition, the
editors of this edition collaborated with the PNO
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has most recently been in private practice and is

and was previously a patent examiner at the U.S.

a former New York assistant first deputy attorney

Patent & Trademark Office.

general. Her term extends until September 2009.
Joseph J. Simmons recently resigned his position
as the director of the Bureau of Competition.
Simmons presided over 60 enforcement actions
during his two years at the Commission, including
25 non-merger cases and two challenges to

policy can also stimulate innovation by rewarding

Rymer in the Central District of California and

Last year the FTC and the Department of Justice

are not inherently in conflict, but any failure to

Associate Justice Sandra Day O’Connor.

jointly held hearings focused on the current

strike the appropriate balance between them can

balance of competition and patent law and policy.

harm innovation.

Competition. Creighton has been deputy director
since August 2001, when she joined the FTC.

Personnel Changes at Both
Antitrust Agencies

She previously clerked for Judge Pamela Ann

Both the

Bruce McDonald recently joined the DOJ and will
serve as the deputy assistant attorney general for
regulatory matters in the Antitrust Division,

Department of

Barry Nigro, Ann Malester and Bruce Hoffman

Justice and Federal

of Competition. Nigro joins the FTC from private

all have become deputy directors of the Bureau

overseeing airline, transportation, energy and
other regulatory matters. McDonald was formerly
in private practice. Robert Kramer, a career
attorney with the Division and for many years
chief of one of its litigation sections, succeeds

practice. Malester has led one of the merger

Trade Commission

groups within the FTC for a number of years.
Hoffman has been the associate director for

have experienced

regional litigation for the past two years.

numerous personnel

David Scheffman resigned his position as director

Connie Robinson as director of operations.
Deborah Majoras, principal deputy attorney
general for Antitrust, recently announced her
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been named the new director of the Bureau of
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after closing, for example, this means that the
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served as director for two years, will return to the

months.
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intention to leave DOJ and is expected to rejoin
the private bar next year. Majoras joined the
Division in the spring of 2001 and was involved
in the General Electric–Honeywell International
and Microsoft cases.
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Federal Trade Commission
Commissioner Sheila Foster Anthony served on
the Commission for nearly six years until her term
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expired recently. Often a dissenting voice,
Commissioner Anthony disagreed with other
commissioners in the cruise industry consolidation,
and in the PepsiCo–Quaker Oats (Gatorade) and
General Mills–Pillsbury merger decisions. Pamela
Jones Harbour recently replaced Commissioner
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private sector as an economic consultant and
adjunct professor at Vanderbilt University. Luke
Froeb will replace Scheffman. Froeb joins the
FTC from the Owen Graduate School of
Management at Vanderbilt University. Froeb was
previously an economist with the Antitrust Division.
The FTC recently enhanced its intellectual property
expertise, evidencing yet more institutional interest

the innovator with a right to exclude others from
making, using or selling the invention claimed by
the patent. As the FTC sees it, the two systems

(See our December, 2001 Antitrust and Trade

Regulation Bulletin at www.haledorr.com/antitrust.)
The hearings spanned more than 24 days,
involving more than 300 panelists and 100
separate written submissions. The first tangible
by-product of those sessions came on October
28, 2003, with the release of a 266-page FTC
report containing specific recommendations for
changes in the existing patent system (the Patent
Report)(http://www.ftc.gov/opa/2003/10/creport
.htm). A second, joint report with DOJ, containing
specific recommendations for antitrust, is promised
for the future.

Although the Patent Report states that “for the

Michelle D. Miller
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The Patent Report begins with a general discussion

contain claims that are overly broad. These poor

of the common aims of both competition and

quality or questionable patents can cause

patent law and policy. Competition stimulates

competitors to forgo R&D in the areas the patent

innovation by spurring the innovation of new or

improperly covers, and can increase the practice

This publication is not intended as legal advice. Readers should not act upon
information contained in this publication without professional legal counseling.

better products or more efficient processes. Patent

of “defensive patenting,” contribute to the “patent
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most part” the patent system achieves a proper
balance with competition policy, it concludes that
in some ways the system is “out of balance.” As
a result, the report makes a number of specific
recommendations for reforming the legal systems,
procedures and institutions of the patent system.
Most, but not all, of the proposals would require
enabling legislation. The FTC’s recommendations
include the following:
1. Measures should be implemented to reduce
the number of invalid patents issued or those that

in this subject. Armando Irizarry and Thomas
Mays joined as counsels for intellectual property.
Irizarry comes from Michigan State University,
where he was teaching law.
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